Du lette etter:

bergenbio investor relations

BerGenBio - Developing first-in-class AXL inhibitors for ...
https://www.bergenbio.com
BerGenBio: Developing first-in-class AXL inhibitors for aggressive diseases, including advanced, treatment resistant cancers.
Investor Relations Contacts - BerGenBio
www.bergenbio.com › investors › investor-relations
Subscribe to our newsletter. Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events.
BerGenBio and Oslo University Hospital Announce the AXL ...
https://www.morningstar.com/news/pr-newswire/20220127io44051/bergenbio...
27.01.2022 · Investor Relations PR Newswire BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients
BerGenBio ASA Stock Price, Quote & History – Euronext Live
https://euronext.earlymetrics.com › ...
Find the latest financial analysis of BerGenBio ASA and other vital information on Euronext Live. ... Investment cash flows, -2,557, -346, -234, 2,279 ...
bergenbio asa: invitation to presentation of second quarter ...
https://live.euronext.com › node
Bergen, Norway, 4 August 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage ... Investors/Financial Reports section. ... ir@bergenbio.com
BERGENBIO (BGBIO) - DN Investor
http://investor.dn.no
15 feb. Vis BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021. 7 feb. Vis BERGENBIO ASA: INVITATION TO FOURTH QUARTER 2021 RESULTS WEBCAST.
BerGenBio ASA (BRRGF) SEC Filings - Nasdaq
https://www.nasdaq.com/market-activity/stocks/brrgf/sec-filings
Find the latest SEC Filings data for BerGenBio ASA (BRRGF) at Nasdaq.com. Skip to main ... Investor Relations ... This information can be used by …
Investors - BerGenBio
www.bergenbio.com › investors
Mar 17, 2022 · Investors. Yearly Reports Annual Report 2020. BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases ...
BerGenBio participation at upcoming healthcare investor and life
https://finansavisen.no › view
BerGenBio ASA: Annual General Meeting Bergen, Norway, 14 May 2018 - The Annual ... 1 June, Sachs Immuno-Oncology BD&L and Investment Forum (Chicago, IL)*
Share Information - BerGenBio
www.bergenbio.com › investors › share-information
Mar 11, 2022 · BerGenBio has not paid any dividends for the year ended 31 December 2020 or any previous year. The Company is focusing on the development of novel pharmaceutical products and does not anticipate paying any cash dividend until sustainable profitability is achieved.
Financial Calendar - BerGenBio
www.bergenbio.com › investors › financial-calendar
May 19, 2021 · 25 February 2021. Annual report 2020. 19 March 2021. Annual General Meeting. 19 May 2021. Quarterly Report – Q1 2021. 17 August 2021. Half-year report 2021. 16 November 2021.
BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND …
https://finance.yahoo.com/news/bergenbio-asa-results-fourth-quarter...
16.02.2022 · BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announces its results for the fourth ...
Investor Relations & Communications Manager - Bergenbio
https://karrierestart.no/ledig-stilling/1540664
Bergenbio - Investor Relations & Communications Manager. Finn drømmejobben gjennom KarriereStart.no - startsiden for jobb og karriere.
BerGenBio ASA - Cision News
https://news.cision.com › bergenbi...
BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of ... Contact: ir@bergenbio.com Rune Skeie, CFO, BerGenBio ASA ...
Investors - BerGenBio
https://www.bergenbio.com/investors
17.03.2022 · Investors. Yearly Reports Annual Report 2020. BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers. Our …
Investors - BerGenBio
https://www.bergenbio.com › inves...
BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug ...
Presentations - BerGenBio
www.bergenbio.com › investors › presentations
BerGenBio regularly presents clinical and pre-clinical data at leading scientific congresses and shares company updates at investor relation conferences. Below are presentations given by the company’s senior management and clinical collaborators. Corporate Presentations 2021 2020 2019 2018 2017 Scientific Presentations 2021 2020 2019 2018 2017
Largest Shareholders - BerGenBio
www.bergenbio.com › investors › our-shareholders
Mar 17, 2022 · Subscribe to our newsletter. Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events.